Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Healthcare
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.


TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Strong Cash Position at exit 2020
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Comment by PitchinPennieson Nov 19, 2020 12:54pm
140 Views
Post# 31933592

RE:RE:RE:RE:RE:RE:Strong Cash Position at exit 2020

RE:RE:RE:RE:RE:RE:Strong Cash Position at exit 2020@Nosepick, that's not exactly a ringing defense of Cap'n Craig, or a denial of the veracity of my statement. Truth is the acting CEO is one of the most widely disliked figures in the sector, except by two or three sad-sack apologists on this board. Ask around. No deals have been done with Suffer Pharmaceuticals, and why do you imagine that would that be? Perhaps because potential partners get angry from having their time wasted by a certain arrogant man-child?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities